Macrophage susceptibility to emactuzumab (RG7155) treatment

Molecular Cancer Therapeutics

Volumn 15, Issue 12, 2016, Pages 3077-3086

  Pradel, Leon P ^a,b   Ooi, Chia Huey ^c   Romagnoli, Solange ^c   Cannarile, Michael A ^a   Sade, Hadassah ^a   Reuttinger, Dominik ^a   Ries, Carola H ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b UNIVERSITY OF SALZBURG   (Austria)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; EMACTUZUMAB; INTERLEUKIN 10; INTERLEUKIN 4; MANNOSE RECEPTOR; MANNOSE RECEPTOR 1; MESSENGER RNA; MITOCHONDRIAL DNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOKINE; MONOCLONAL ANTIBODY; STAT1 PROTEIN;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER TISSUE; CELL HYPOXIA; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MULTICENTER STUDY (TOPIC); NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; BIOPSY; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOPHENOTYPING; MACROPHAGE; METABOLISM; MONOCYTE; NEOPLASM; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; SKIN; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS; BIOPSY; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DRUG RESISTANCE; HUMANS; IMMUNOPHENOTYPING; MACROPHAGES; MONOCYTES; NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; SKIN; STAT1 TRANSCRIPTION FACTOR;

EID: 85008311451     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0157     Document Type: Article

References (46)

1. Joyce JA, Pollard JW.Microenvironmental regulation ofmetastasis. Nat Rev Cancer 2009;9:239-52.
2. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015;27:462-72.
3. DeNardo DG, BrennanDJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:OF52-65.
4. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-Associated macrophages and survival in classic Hodgkin lymphoma. N Engl J Med 2010;362:875-85.
5. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-Associated macrophages in solid tumor: A metaanalysis of the literature. PLoS One 2012;7:e50946.
6. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
7. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
8. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-Associated macrophages with Anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846-59.
9. Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile M, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-Type tenosynovial giant cell tumours of the soft tissue: A dose-escalation and dose-expansion phase 1 study. Lancet Oncol 2015;16:949-56.
10. Ries CH, Hoves S, Cannarile MA, Ruettinger D. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol 2015;23:45-51.
11. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013;19:1264-72.
12. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-34.
13. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26.
14. LindeN, Lederle W, Depner S, van RooijenN, Gutschalk CM, Mueller MM. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol 2012;227:17-28.
15. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010;70:5728-39.
16. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11:889-96.
17. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593-604.
18. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014;41:14-20.
19. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-11.
20. Kang HG, Lee SY, Jeon HS, Choi YY, Kim S, Lee WK, et al. A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females. J Thorac Oncol 2014;9:1647-55.
21. Rey-Giraud F, Hafner M, Ries CH. In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions. PLoS One 2012;7:e42656.
22. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009;28:461-8.
23. Chen T, Srinivas C. Group sparsity model for stain unmixing in brightfield multiplex immunohistochemistry image. Comput Med Imaging Graph 2015;46 Pt 1;30-9.
24. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5:621-8.
25. McVean GA. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012;491:56-65.
26. Hsouna S, BenHalim N, Lasram K, MeiloudG, Arfa I, Kerkeni E, et al. Study of the T16189C variant and mitochondrial lineages in Tunisian and overall Mediterranean region. Mitochondrial DNA A DNA Mapp Seq Anal 2016;27:1558-63.
27. Ahmed N, Dhanapala P, Suphioglu C. Identification and characterization of a novel IL-4 receptor a chain (IL-4Ra) antagonist to inhibit IL-4 signalling. Cell Physiol Biochem 2015;36:831-42.
28. Erkel G, Rether J, Anke T. S14-95, a novel inhibitor of the JAK/STAT pathway from a penicillium species. J Antibiot 2003;56:337-43.
29. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol. 2004; 75:163-89.
30. Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep 2015;12:1902-14.
31. Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009;114:1289-98.
32. Felix J, De Munck S, Verstraete K, Meuris L, Callewaert N, Elegheert J, et al. Structure and assembly mechanism of the signaling complex mediated by human CSF-1. Structure 2015;23:1621-31.
33. AndersenMN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): implications in multiple myeloma. Leuk Res 2015;39:9713529.
34. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005;11:2576-82.
35. Wang Y, Xu B, Hu WW, Chen LJ, Wu CP, Lu BF, et al. High expression of CD11c indicates favorable prognosis in patients with gastric cancer. World J Gastroenterol 2015;21:9403-12.
36. Novak U, Harpur AG, Paradiso L, Kanagasundaram V, Jaworowski A, Wilks AF, et al. Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood 1995;86: 2948-56.
37. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 1992;176:287-92.
38. Renz H, Jujo K, Bradley KL, Domenico J, Gelfand EW, Leung DY. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 1992;99:403-8.
39. Erb KJ, Rueger B, von Brevern M, Ryffel B, Schimpl A, Rivett K. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-Type disorders in mice. J Exp Med 1997;185:329-40.
40. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-Associated macrophages to promote cancer growth and invasion. Gene Dev 2010;24:241-55.
41. Trapnell BC, Whitsett JA. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 2002;64:775-802.
42. Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, et al. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. J Exp Med 2013;210:2477-91.
43. Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeboeller H, et al. Influence of common genetic variation on lung cancer risk: metaanalysis of 14 900 cases and 29 485 controls. Hum Mol Genet 2012; 21:4980-95.
44. Liou CW, Lin TK, Chen JB, Tiao MM, Weng SW, Chen SD, et al. Association between a common mitochondrial DNA D-loop polycytosine variant and alteration ofmitochondrial copy number in human peripheral blood cells. J Med Genet 2010;47:723-8.
45. Liu VWS, Wang Y, Yang HJ, Tsang PCK, Ng TY, Wong LC, et al. Mitochondrial DNAVariant 16189TC is associated with susceptibility to endometrial cancer. Hum Mutat 2003;22:173-4.
46. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab 2012;15:432-7.